RxDoctor Payments Data

Holly Borchers Ellinger

Acute Care · Celina, OHNPI 1437454873

Payments from drug & device makers

$2,443in general payments, 2019–2025

Across 68 payments — averaging $35.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$782
  • Medtronic$416
  • Laborie Medical Technologies Corp.$400
  • Johnson & Johnson$267
  • Pfizer$186
  • Myovant Sciences Inc.$146
  • plus $246 from 7 others

What the payments were for

  • Travel & lodging$1416%
  • Food & beverage$1,44359%
  • Education$85935%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,443 in reported general payments places this provider in the 90th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$140,721
Medicare patients
764
Services billed
2,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$156,281
MyrbetriqMirabegron176$136,031
OrgovyxRelugolix21$56,725
GemtesaVibegron53$51,505
Methenamine Hippurate165$14,837
Tamsulosin Hcl823$13,953
Solifenacin Succinate125$11,062
Trospium Chloride129$9,666
Mirabegron ErMirabegron13$7,636
Finasteride409$6,279
Potassium Citrate ErPotassium Citrate42$5,754
Oxybutynin Chloride ErOxybutynin Chloride130$3,932
Estradiol33$1,987
Silodosin19$1,913
Oxybutynin Chloride93$1,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$782$292,312187 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$59$108,23074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,101 acute care providers in Ohio.

Other acute care in Celina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →